Clinical Trials Directory

Trials / Completed

CompletedNCT00549666

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Sumitomo Pharma America, Inc. · Industry
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen

Conditions

Interventions

TypeNameDescription
DRUGLurasidone 40 mgLurasidone 40 mg days 12-21 once daily
DRUGPlacebo 40 mgPlacebo 40 mg once daily during treatment period
DRUGOrtho Tri-CyclenOrtho Tri-Cyclen during 28-day lead in period

Timeline

Start date
2007-08-01
Primary completion
2007-12-01
Completion
2007-12-01
First posted
2007-10-26
Last updated
2011-09-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00549666. Inclusion in this directory is not an endorsement.